A Phase 1 interventional study of Rosuvastatin and ACT-541468 in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Czechia. Open to male participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-11.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study in healthy male subjects to investigate whether administration of ACT-541468 can affect the fate in the body (amount and time of presence in the blood) of rosuvastatin
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rosuvastatin Day 1
Drug: Rosuvastatin
ACT-541468 Day 5 to Day 7
Drug: ACT-541468
Rosuvastatin Day 8; ACT-541468 Day 8 to Day 12
Drug: Rosuvastatin · Drug: ACT-541468
10 mg tablet
25 mg hard capsule
Effect of ACT-541468 at steady-state on Cmax of single-dose rosuvastatin
Effect of ACT-541468 at steady-state on Cmax of single-dose rosuvastatin
Time frame: During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.
Effect of ACT-541468 at steady-state on tmax of single-dose rosuvastatin
Effect of ACT-541468 at steady-state on tmax of single-dose rosuvastatin
Time frame: During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.
Effect of ACT-541468 at steady-state on AUC0-t of single-dose rosuvastatin
Effect of ACT-541468 at steady-state on AUC0-t of single-dose rosuvastatin
Time frame: During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.
Effect of ACT-541468 at steady-state on AUC0-∞ of single-dose rosuvastatin
Effect of ACT-541468 at steady-state on AUC0-∞ of single-dose rosuvastatin
Time frame: During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.
Effect of ACT-541468 at steady-state on t½ of single-dose rosuvastatin
Effect of ACT-541468 at steady-state on t½ of single-dose rosuvastatin
Time frame: During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.
Trough concentration (Ctrough) of ACT-541468
Trough concentration (Ctrough) of ACT-541468
Time frame: During ACT-541468 administration (Treatment B1 and B2); i.e. for about 1 week
Change in vital signs
Change from baseline to each time point of measurement during each treatment in vital signs (supine BP and pulse rate)
Time frame: From Screening to EOS (for a maximum of up to 5 weeks)
Change in ECG variables
Change from baseline to each time point of measurement during each treatment in ECG variables
Time frame: From Screening to EOS (for a maximum of up to 5 weeks)
Treatment-emergent (serious) adverse events
Treatment-emergent AEs and SAEs during each treatment
Time frame: From Screening to EOS (for a maximum of up to 5 weeks)
Treatment-emergent ECG abnormalities
Treatment-emergent ECG abnormalities during each treatment
Time frame: From Screening to EOS (for a maximum of up to 5 weeks)
Change in body weight
Change from baseline to each time point of measurement during each treatment in body weight
Time frame: From Screening to EOS (for a maximum of up to 5 weeks)
Change in clinical laboratory tests
Change from baseline to each time point of measurement during each treatment in clinical laboratory tests
Time frame: From Screening to EOS (for a maximum of up to 5 weeks)
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2017 to primary completion in Dec 2017, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daridorexant
Idorsia Pharmaceuticals Ltd. →